<DOC>
	<DOCNO>NCT00072527</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , irinotecan , carboplatin , etoposide , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness cisplatin irinotecan follow carboplatin , etoposide , radiation therapy treat patient limited-stage small cell lung cancer .</brief_summary>
	<brief_title>Cisplatin Irinotecan Followed Carboplatin , Etoposide , Radiation Therapy Treating Patients With Limited-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy cisplatin irinotecan follow carboplatin , etoposide , radiotherapy , term 2-year survival , patient limit stage small cell lung cancer . Secondary - Determine overall response rate , overall survival , failure-free survival patient treat regimen . - Determine response rate patient treat induction therapy comprise irinotecan cisplatin . - Determine toxicity tolerability regimen patient . OUTLINE : This multicenter study . - Induction therapy : Patients receive cisplatin IV 60 minute irinotecan IV 90 minute day 1 8 . Treatment repeat every 21 day 2 course absence disease progression unacceptable toxicity . - Consolidation therapy : Immediately completion induction therapy , patient receive carboplatin IV 60 minute day 1 etoposide IV 60 minute day 1-3 . Treatment repeat every 21 day 3 course absence disease progression unacceptable toxicity . - Radiotherapy : Beginning day 1 consolidation therapy , patient undergo chest radiotherapy daily 5 day week 6-7 week . After completion consolidation therapy , patient achieve complete remission good partial remission may undergo prophylactic radiotherapy brain . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 75 patient accrue study within 15-24 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . Histologically cytologically document small cell lung cancer limit stage . 1.1 Limited stage disease category include patient disease restrict one hemithorax regional lymph node metastasis , include hilar , ipsilateral contralateral mediastinal lymph node . 1.2 Although usually define limited stage small cell lung cancer , concern volume radiation field would require , patient clinically suspect confirmed supraclavicular lymph node metastasis , patient pathologically enlarge contralateral hilar lymph node , patient pleural effusion visible plain chest radiograph , whether cytologically positive , NOT eligible . 2 . All Patients must Measurable Disease 2.1 Lesions accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ≥10 mm spiral CT scan . 2.2 Pleural/pericardial effusion consider measurable . 3 . Age ≥18 4 . ECOG Performance status 02 . 5 . Prior Treatment No prior chemotherapy radiotherapy SCLC . 6 . No `` currently active '' second malignancy nonmelanoma skin cancer . Patients consider `` currently active '' malignancy complete therapy consider physician less 30 % risk relapse . 7 . Nonpregnant nonnursing significant risk fetus/infant . 8 . Required Initial Laboratory Values Granulocytes ≥1,500/µl Platelets ≥100,000/µl Serum Creatinine ≤ULN Bilirubin &lt; 1.5 mg/dl SGOT ( AST ) &lt; 2 x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>